Warfarin and Non-Steroidal Anti-Inflammatory Drugs (NSAID) Customized Alert
The hypothesis is that a newly formatted electronic alert that requires the prescriber to pause and enter a specific "reason for override" on this alert, will cause prescribers in the intervention group to be significantly less likely to prescribe the combination of warfarin and NSAID than prescribers in the control group.
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Caregiver)
|Official Title:||The Effect of Customized Alerts Versus Generic Alerts for the Prescription of Warfarin and NSAID|
- Decreased rate of prescription of the combination of warfarin and NSAID [ Time Frame: 17 months ] [ Designated as safety issue: Yes ]
|Study Start Date:||August 2006|
|Study Completion Date:||December 2007|
|Primary Completion Date:||December 2007 (Final data collection date for primary outcome measure)|
Experimental: customized electronic alert
This intervention was not targeted to patients with a disease but to the providers. The intervention was not a drug but a customized electronic alert, requesting the prescriber to specify a "reason for override" whenever the combination drugs of warfarin and NSAID were ordered together.
|Behavioral: Electronic Alert|
No Intervention: Standard practice
The control group was not patients but the providers. Providers in the control group continued with the standard practice of receiving passive alerts in the form of message boxes warning the provider not to prescribe the combination drugs warfarin and NSAID.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00880932
|United States, Pennsylvania|
|Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center|
|Phila, Pennsylvania, United States, 19104|